Overview

Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm 2 will receive early combination conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Arm 3 will receive early tumour necrosis factor (TNF) inhibitor therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oxford
Treatments:
Adalimumab
Leflunomide
Methotrexate
Sulfasalazine